Skip to main content

Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.

Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ

Publication: Clin Cancer Res (2009) • Vol 15 • Page 7003-11PMID: 19887485View on PubMed

Purpose

The purpose of this paper was to compare estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2(HER2) status determination in breast tumors by DNA microarray and immunohistochemistry (IHC) using different scoring methods.

Conclusion

Concordance of ER, PR and HER2 status between each of three scoring methods for IHC and DNA microarray determination was high. The different scoring methods employed and the use of tissue microarrays (TMAs) instead of whole sections had no significant effects on ER, PR, or HER2 status.

Studies (1)

Purpose

The purpose of this study was to determine the effects of IHC scoring method, analysis of whole sections rather than TMAs, and evaluation by IHC versus chromogenic in situ hybridization (CISH) on the concordance of ER, PR and HER2 status of breast tumors. Results were compared with those obtained by DNA microarray. For the tissue microarrays, 3 cores were examined per case, and ER and PR IHC positivity was defined as more than 10% of tumor cells staining (central scoring). HER2 IHC was scored on a 4 point scale with positivity defined as complete membrane staining in more than 10% of cells. HER2 CISH was used to determine HER2 status of borderline cases with positivity defined as at least 6 CISH spots.

Summary of Findings

IHC results using central scoring and DNA microarray results were strongly correlated (r=0.77, 0.61, and 0.76 for ER, PR and HER2, respectively) with agreement of results in 93, 83 and 96% of cases for ER, PR and HER2 respectively. Non-concordant results for ER and PR generally arose from positive microarray results and negative immunohistochemical scoring, while the reverse was true for HER2 status. In cases that were preselected based on high concordance of IHC results between local and central scoring methods, concordance rates between DNA microarray results and IHC results in whole sections using local, central and ASCO/CAP scores were 92, 93 and 92%, respectively for ER, 84, 81, and 86%, respectively for PR, and 93, 95 and 94%, respectively for HER2. Concordance rates were similarly high between DNA microarrays and IHC staining of TMAs or whole sections. Of 11 cases with discordant IHC results between central and ASCO/CAP scoring, 5 were able to be classified after DNA microarray analysis.
  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    RNADNA microarray
    ProteinTissue microarray
    ProteinImmunohistochemistry
    DNAIn situ hybridization
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsType of slide
    Tissue microarray
    Whole tissue section
    Immunohistochemistry SpecificData handling
    ASCO/CAP scoring
    Central scoring
    Local scoring
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    PR
    DNA microarray SpecificTargeted nucleic acid
    ER
    HER2
    PR
    DNA microarray SpecificTechnology platform
    IHC